MTOR and diabetic kidney disease: Studies have demonstrated that mTOR inhibitors, such as rapamycin, can reduce mTORC1 activity, thereby promoting autophagy, reducing oxidative stress and inflammation, and alleviating the progression of DKD (Lin et al., 2021).